Onconetix (ONCO) Operating Expenses (2021 - 2026)
Onconetix (ONCO) posted quarterly Operating Expenses of $10.2 million for Q1 2026, down 18.96% year-over-year from $12.6 million in Q1 2025, and up 568.66% quarter-over-quarter from $1.5 million in Q4 2025.
Onconetix (ONCO) Operating Expenses (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Operating Expenses for 6 consecutive years, with $10.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 18.96% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at $16.1 million (down 72.67% YoY), while the FY2025 annual figure was $18.5 million, down 67.87% from the prior year.
- Operating Expenses improved to $10.2 million in Q1 2026 per ONCO's latest filing, from $1.5 million in the prior quarter.
- Across five years, Operating Expenses topped out at $29.8 million in Q4 2024 and bottomed at $1.5 million in Q4 2025.
- Historically, Operating Expenses has averaged $7.9 million across 5 years, with a median of $4.3 million in 2022.
- Annual changes were most pronounced in 2023 — Operating Expenses surged 544.54% — and 2025, when it plunged 94.87%.
- Onconetix's Operating Expenses stood at $3.2 million in 2022, then soared by 544.54% to $20.9 million in 2023, then soared by 42.47% to $29.8 million in 2024, then slumped by 94.87% to $1.5 million in 2025, then jumped by 568.66% to $10.2 million in 2026.
- Business Quant data shows ONCO's Operating Expenses at $10.2 million in Q1 2026, $1.5 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 541.02 Mn |
| 10 | Onconetix | 1.44 Mn | -4.51 Mn | 4,303.00 | 2.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.74 Mn |
| Mar 31, 2026 | 10.22 Mn |
| Dec 31, 2025 | 1.53 Mn |
| Sep 30, 2025 | 2.34 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Mar 31, 2025 | 12.62 Mn |
| Dec 31, 2024 | 29.81 Mn |
| Sep 30, 2024 | 2.75 Mn |
| Jun 30, 2024 | 13.72 Mn |
| Mar 31, 2024 | 11.27 Mn |
| Dec 31, 2023 | 20.92 Mn |
| Sep 30, 2023 | 4.49 Mn |
| Jun 30, 2023 | 6.65 Mn |
| Mar 31, 2023 | 2.85 Mn |
| Dec 31, 2022 | 3.25 Mn |
| Sep 30, 2022 | 3.87 Mn |
| Jun 30, 2022 | 4.29 Mn |
| Mar 31, 2022 | 2.07 Mn |
| Dec 31, 2021 | 1.20 Mn |
| Sep 30, 2021 | 1.10 Mn |